{"id":"cldm-1-gel-twice-daily","safety":{"commonSideEffects":[{"rate":null,"effect":"Dryness or peeling of skin"},{"rate":null,"effect":"Erythema or irritation at application site"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Gram-negative folliculitis (with prolonged use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin works by binding to the bacterial 50S ribosomal subunit and inhibiting peptide bond formation, thereby preventing bacterial protein synthesis. This bacteriostatic mechanism is effective against a broad range of gram-positive and anaerobic bacteria. The topical gel formulation delivers the antibiotic directly to affected skin areas, making it particularly useful for treating acne and other dermatological infections.","oneSentence":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:18.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris (topical treatment)"},{"name":"Bacterial skin infections"}]},"trialDetails":[{"nctId":"NCT02557399","phase":"PHASE4","title":"DUAC® Early Onset Efficacy Study in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-07","conditions":"Acne Vulgaris","enrollment":350},{"nctId":"NCT01445301","phase":"PHASE3","title":"Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-27","conditions":"Acne Vulgaris","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CLDM"],"phase":"phase_3","status":"active","brandName":"CLDM 1% gel twice daily","genericName":"CLDM 1% gel twice daily","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acne vulgaris (topical treatment), Bacterial skin infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}